197 related articles for article (PubMed ID: 22280188)
1. The European value-pricing game.
McGuire A
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):5-6. PubMed ID: 22280188
[No Abstract] [Full Text] [Related]
2. Pharmaceutical expenditure compared across countries.
van Mosseveld C
Can J Clin Pharmacol; 2005; 12(3):e269-75. PubMed ID: 16373959
[TBL] [Abstract][Full Text] [Related]
3. Drug industry is considering more use of differential pricing, conference hears.
Sukkar E
BMJ; 2011 Dec; 343():d8049. PubMed ID: 22155726
[No Abstract] [Full Text] [Related]
4. Drug price deal spells windfall for researchers.
Bosch X
Nature; 2001 Nov; 414(6860):138. PubMed ID: 11700514
[No Abstract] [Full Text] [Related]
5. Market watch: pricing strategies for emerging markets.
Lineberry N; Snyder E; Gunda S
Nat Rev Drug Discov; 2011 Aug; 10(8):567. PubMed ID: 21804586
[No Abstract] [Full Text] [Related]
6. Convergence of decision rules for value-based pricing of new innovative drugs.
Gandjour A
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
[TBL] [Abstract][Full Text] [Related]
7. Differential pricing of new pharmaceuticals in lower income European countries.
Kaló Z; Annemans L; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
[TBL] [Abstract][Full Text] [Related]
8. How New Zealand has contained expenditure on drugs.
Cumming J; Mays N; Daubé J
BMJ; 2010 May; 340():c2441. PubMed ID: 20483927
[No Abstract] [Full Text] [Related]
9. Mega-mergers in the pharmaceutical industry. In whose interests?
Po AL
Pharmacoeconomics; 1998 Oct; 14(4):349-55. PubMed ID: 10344903
[TBL] [Abstract][Full Text] [Related]
10. Reference pricing of pharmaceuticals.
Brekke KR; Königbauer I; Straume OR
J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.
Ogbighele E
IDrugs; 2010 May; 13(5):317-20. PubMed ID: 20432188
[TBL] [Abstract][Full Text] [Related]
12. Goodbye Columbus! New NRDOs forego discovery.
Thiel KA
Nat Biotechnol; 2004 Sep; 22(9):1087-92. PubMed ID: 15340473
[No Abstract] [Full Text] [Related]
13. Pricing pharmaceutical compounds under development.
Dimitri N
Trends Pharmacol Sci; 2014 May; 35(5):217-8. PubMed ID: 24439477
[No Abstract] [Full Text] [Related]
14. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
Martikainen J; Kivi I; Linnosmaa I
Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
[TBL] [Abstract][Full Text] [Related]
15. Medicines pricing singled out.
Buchanan E
S Afr Med J; 2004 May; 94(5):334. PubMed ID: 15211941
[No Abstract] [Full Text] [Related]
16. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.
Buckely M
Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760
[No Abstract] [Full Text] [Related]
17. Pharmaceutical reference prices. How do they work in practice?
Dickson M; Redwood H
Pharmacoeconomics; 1998 Nov; 14(5):471-9. PubMed ID: 10344913
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical expenditure and therapeutic value of new medicines in Spain.
Darba J
Pharmacoeconomics; 2003; 21(16):1211-2. PubMed ID: 14594440
[No Abstract] [Full Text] [Related]
19. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
Werling K; Abraham S; Strelec J
J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
[No Abstract] [Full Text] [Related]
20. Costing drug development.
Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
[No Abstract] [Full Text] [Related]
[Next] [New Search]
